Representative Data for Systemic Tregs and Immunomodulation Credit: Coya Therapeutics, Inc. COYA 303 is an investigational proprietary biologic combination of low-dose (LD)-IL-2 and GLP-1 receptor agonist (RA) for subcutaneous administration with potential for treating inflammation-driven diseases like Alzheimer's Disease, and other neurodegenerative and autoimmune diseases COYA 303 significantly reduced peripheral… Read More..

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a technology-enabled financial services platform modernizing trading, clearing, settlement, and banking, today announced that it will present at the ThinkEquity Conference being held at the Mandarin Oriental, New York on Thursday, October… Read More..

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights… Read More..